Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA

Barbora Brodská, Petra Otevřelová, Aleš Holoubek

. 2011 ; 350 (1-2) : 71-80.

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027913

Grantová podpora
NS9637 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek
Zdroj

E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2011-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem

Restoration of cellular apoptotic pathways plays a crucial role in cancer therapy strategies. In a broad spectrum of anticancer drugs, epigenetic effectors are in the center of interest mostly because of potential reversibility of their action. Methylation status of the cells is influenced by methyltransferase inhibitor 2-deoxy-5'-azacytidine (decitabine, DAC), but higher concentrations of this agent cause a DNA-damage. In our study, tumor supressor p53-apoptotic pathway was activated in decitabine-induced cell death. Expression of p53-inducible BH3-only apoptotic proteins Puma and Noxa was elevated and large activation of executive caspases was observed. The extent of acetylation in the cell is affected by histonedeacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Combination of SAHA with decitabine brought synergistic effect on apoptosis triggering in CML-T1 cell line, but apoptosis as well as necrosis occurred also in normal peripheral blood lymphocytes. Therefore, promising potential of such combined therapy calls for more detailed investigation of unwanted effects in normal cells.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027913
003      
CZ-PrNML
005      
20141022122819.0
007      
ta
008      
120817s2011 ne f 000 0#eng||
009      
AR
024    7_
$a 10.1007/s11010-010-0683-3 $2 doi
035    __
$a (PubMed)21153863
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Brodská, Barbora $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. brodska@uhkt.cz
245    10
$a Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA / $c Barbora Brodská, Petra Otevřelová, Aleš Holoubek
520    9_
$a Restoration of cellular apoptotic pathways plays a crucial role in cancer therapy strategies. In a broad spectrum of anticancer drugs, epigenetic effectors are in the center of interest mostly because of potential reversibility of their action. Methylation status of the cells is influenced by methyltransferase inhibitor 2-deoxy-5'-azacytidine (decitabine, DAC), but higher concentrations of this agent cause a DNA-damage. In our study, tumor supressor p53-apoptotic pathway was activated in decitabine-induced cell death. Expression of p53-inducible BH3-only apoptotic proteins Puma and Noxa was elevated and large activation of executive caspases was observed. The extent of acetylation in the cell is affected by histonedeacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Combination of SAHA with decitabine brought synergistic effect on apoptosis triggering in CML-T1 cell line, but apoptosis as well as necrosis occurred also in normal peripheral blood lymphocytes. Therefore, promising potential of such combined therapy calls for more detailed investigation of unwanted effects in normal cells.
650    _2
$a protinádorové antimetabolity $x farmakologie $7 D000964
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $7 D000971
650    _2
$a apoptóza $x účinky léků $x genetika $7 D017209
650    _2
$a proteiny regulující apoptózu $x genetika $x metabolismus $7 D051017
650    _2
$a azacytidin $x analogy a deriváty $x farmakologie $7 D001374
650    _2
$a kultivované buňky $7 D002478
650    _2
$a preklinické hodnocení léčiv $7 D004353
650    _2
$a synergismus léků $7 D004357
650    _2
$a regulace genové exprese u leukemie $x účinky léků $7 D015973
650    _2
$a lidé $7 D006801
650    _2
$a kyseliny hydroxamové $x farmakologie $7 D006877
650    _2
$a chronická myeloidní leukemie $x genetika $x metabolismus $x patologie $7 D015464
650    _2
$a lymfocyty $x účinky léků $x metabolismus $7 D008214
650    _2
$a protoonkogenní proteiny $x genetika $x metabolismus $7 D011518
650    _2
$a protoonkogenní proteiny c-bcl-2 $x genetika $x metabolismus $7 D019253
650    _2
$a upregulace $x účinky léků $x genetika $7 D015854
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Otevřelová, Petra $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Holoubek, Aleš $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
773    0_
$w MED00003385 $t Molecular and cellular biochemistry $x 1573-4919 $g Roč. 350, č. 1-2 (2011), s. 71-80
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21153863 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20141022122817 $b ABA008
999    __
$a ok $b bmc $g 949955 $s 785259
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 350 $c 1-2 $d 71-80 $i 1573-4919 $m Molecular and cellular biochemistry $n Mol Cell Biochem $x MED00003385
GRA    __
$a NS9637 $p MZ0
LZP    __
$a Pubmed-20120817/11/03

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...